Max Krakowiak: Yes. I think I mentioned that earlier as well in one of the responses. I do probably – we do probably anticipate that to continue here in the first quarter. But I think as we look over in the full year for applied genomics, we probably expect it to be slightly down from this year on a non-COVID basis. So in 2022, it was high single-digits. We probably expect it for the full year to be slightly below that, but we do expect it to rebound sort of after the first quarter here.
Jack Meehan: Got it. Thank you, Max.
Operator: Thank you. Our next question for today comes from Paul Knight of KeyBanc. Paul, your line is now open. Please go-ahead.
Paul Knight: Hi, Prahlad. Is the – are the advances in spatial biology and faster flow cytometry, is this accelerating do you think the market for BioLegend or closed systems kind of keeping it where it’s been? So kind of what’s your opinion on this dynamic going forward for BioLegend?
Prahlad Singh: I think spatial biology and proteomics and all of that is a growing area, Paul. But I think BioLegend and our Life Sciences research reagents business overall is a very strong portfolio that we are able to now deploy globally with the channels that we have access to that BioLegend didn’t have. So I think the growth trajectory over the next foreseeable future just is in terms of providing the commercial footprint, the infrastructure, the capabilities and competencies of overall PerkinElmer rather than one particular area of growth.
Paul Knight: And then last, regarding – with your better – I shouldn’t say better, bigger platform, I would assume your M&A pipeline looks pretty robust now going into the next couple of years.
Prahlad Singh: Yes. We will continue to be acquisitive as we have been, and we continue – we will continue to add growth trajectories to our portfolio given that we will have a robust balance sheet and we’ll have an even more robust balance sheet post the divestiture.
Paul Knight: Okay, thank you.
Operator: Thank you. Our next question comes from Max Masucci from Cowen. Max, your line is now open. Please go-ahead.
Max Masucci: Hi, thanks for taking the questions. First one, there is a GMA publication released last week. It was supporting broader use of rapid whole genome sequencing, for instance, – which today I believe is included in around six state Medicaid policies in the US. So it would be great to hear just generally your latest outlook for new reimbursement wins for newborn screening in the US this year, if that’s changed at all?
Prahlad Singh: Max, as you know very well, today, the way that newborn screening is done, that the states pay for it, right, it’s not reimbursed. It’s sort of – it’s not a private insurance or an insurance reimbursement play. And I think the way our view of this is that going forward, newborn screening will continue to be mandated by the states and by RUSP and by the newborn screening law. In terms of rapid genome sequencing, as you said, for newborns, that as you – is going to be an area of interest for us and for others. There are certain regions where we are playing a role in it. But I think it will continue to be more esoteric and specialized for the foreseeable future. The cost the turnaround and the speed and the scale and magnitude, by which newborn screening is done by the state labs today is unmatched and it will continue to be so.
Max Masucci: That’s great, very helpful color, final one from me. It’s nice to see the strong organic growth in the life sciences continuing operations, It would be great to hear some additional detail around the growth that you saw in the quarter for the legacy life sciences reagents business versus BioLegend and then sort of where we are in terms of realizing the operational synergies between BioLegend and the legacy Perkin reagent business?
Max Krakowiak: Yes, so maybe I’ll answer the first question on the growth rates, and then I’ll let Prahlad talk about the synergies here Max. So – again from an overall reagent standpoint in both the fourth quarter and the full year, we’ve performed at a low double-digit. I would say that was pretty consistent across all, our reagent portfolio, there’s not one shining star versus another. So I think we’re pleased overall with our reagents growth across everything from BioLegend, just bio some of our legacy reagent product lines, et-cetera. It was strong growth overall for everybody.
Prahlad Singh: Yes and just to add to that BioLegend has a really strong team and the leadership there has worked with PerkinElmer team in terms of identifying exploring and now executing on synergistic opportunities and it’s not just around commercial and operational, but also around technology and how do we continue to close the gap and the bridge between life sciences and diagnostics. So I think on all fronts, the teams are firing on all cylinders there, could not be more happy about that.
Max Masucci: Great, thanks for taking the questions.
